BMO Capital analyst Juan C. Sanabria maintained a Hold rating on Sabra Healthcare REIT today and set a price target of $22.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Juan C. Sanabria has given his Hold rating due to a combination of factors influencing Sabra Healthcare REIT’s performance. The company’s third-quarter 2025 funds available for distribution (FAD) exceeded market expectations, although its funds from operations (FFO) fell short. Despite this mixed performance, the guidance for FAD was maintained above market predictions, indicating a stable outlook.
However, challenges remain, particularly concerning Sabra’s cost of capital, which is reflected in its valuation metrics such as the 12.4x 2026 estimated AFFO and a 7.7% implied cap rate. While the year-to-date acquisition activity appears robust with a healthy pipeline, these capital cost issues may limit upside potential. Consequently, the Hold rating reflects a balanced view of positive operational performance against financial constraints.
According to TipRanks, C. Sanabria is a 2-star analyst with an average return of 0.5% and a 45.73% success rate. C. Sanabria covers the Real Estate sector, focusing on stocks such as Ventas, Federal Realty, and Brixmor Property.